Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

NCT03200691 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Neoplasms
Esophageal Diseases

Interventions

RADIATION: 3-DCRT or IMRT radiation
DRUG: anti-PD-1 antibody SHR-1210

Sponsor

Hangzhou Cancer Hospital

Collaborators

[object Object]